CSTL News

ACG 2026 Data Show TissueCypher Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus ACG 2026 Data Show TissueCypher Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's EsophagusPR NewswireFRIENDSWOOD, Texas, Oct. 12, 2026Studies...

Late-Breaking EADV 2026 Data Support Use of DecisionDx-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management Late-Breaking EADV 2026 Data Support Use of DecisionDx-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical ManagementPR NewswireFRIENDSWOOD, Texas, Sept. 30...

New Study Shows That TissueCypher Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus New Study Shows That TissueCypher Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's EsophagusPR...

Castle Biosciences to Open New Laboratory Facility in Scottsdale Castle Biosciences to Open New Laboratory Facility in ScottsdalePR NewswireFRIENDSWOOD, Texas, Sept. 22, 2026 New 55,000-square-foot facility expands Castle's operational footprint in Arizona to support growing test volumes and...

New Decision Modeling Study Demonstrates TissueCypher Significantly Improves Risk-Aligned Management for Patients with Barrett's Esophagus New Decision Modeling Study Demonstrates TissueCypher Significantly Improves Risk-Aligned Management for Patients with Barrett's EsophagusPR...

JAAD Publication Shows Improved Performance of DecisionDx-SCC JAAD Publication Shows Improved Performance of DecisionDx-SCC PR Newswire FRIENDSWOOD, Texas, Sept. 9, 2026 DecisionDx-SCC shows enhanced performance with the integration of select clinicopathologic risk factors, providing a more precise...

SciBase receives additional order from Castle Biosciences, advancing the collaboration SciBase receives additional order from Castle Biosciences, advancing the collaboration PR Newswire STOCKHOLM, Sept. 8, 2026 STOCKHOLM, Sept. 8, 2026 /PRNewswire/ -- SciBase Holding AB("SciBase") (STO: SCIB), a...

Does Castle Biosciences, Inc. (CSTL) have what it takes to be a top stock pick for momentum investors? Let's find out.

The consensus price target hints at a 31.5% upside potential for Castle Biosciences (CSTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.